Program Director/Principal Investigator (Last, First, Middle):



BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE
Gorlick, Richard	Professor of Pediatrics and Molecular Pharmacology. Vice Chairman and Division Chief, Pediatric Hematology-Oncology
eRA COMMONS USER NAME (credential, e.g., agency login) Gorlickr	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	MM/YY	FIELD OF STUDY
Brooklyn College, Brooklyn, NY	B.S.	06/1987	Chemistry
SUNY Health Science Center, Brooklyn, NY	M.D.	06/1990	Medicine
Babies Hospital, Columbia Presbyterian		06/1993	Pediatric Residency
Memorial Sloan-Kettering Cancer Center		06/1996	Hematol/Oncol Fellowship

A. Personal Statement

I lead a molecular pharmacology research laboratory focused on studying mechanisms of drug resistance and pathogenesis in osteosarcoma. My laboratory is a Bone Tumor Resource Laboratory for the Children's Oncology Group and is a member of the Pediatric Preclinical Testing Program screening drugs through osteosarcoma xenografts models. I am a practicing pediatric oncologist who is active in clinical trials. I serve as the Chairman of the Bone Tumor Disease Committee for the Children's Oncology Group and a member of the Clinical Research Committee of the Sarcoma Alliance for Research through Collaboration. I am the Treasurer for the Connective Tissue Oncology Society. I have served as the principal investigator both at the national and local level for several clinical trials. I am the Division Chief of Pediatric Hematology-Oncology and Vice Chairman of the Department of Pediatrics at The Children's Hospital at Montefiore.

B. Positions and Honors



1994-1998	Research Fellow, Dr. Joseph Bertino's Laboratory, Memorial Sloan-Kettering Cancer Center
1996-1997	ASCO Young Investigator Award
1996-1998	Clinical Instructor, Pediatrics, Memorial Sloan-Kettering Cancer Center
1998-Present	Director, Bone Tumor Resource Laboratory, Children's Oncology Group (COG)
1998- 2000	American Society of Hematology Junior Faculty Scholar Award
1998-2001	American Society of Clinical Oncology Career Development Award
1998-2004	Assistant Attending, Pediatrics, Memorial Sloan-Kettering Cancer Center
1998-2004	Director, Pediatric Sarcoma Research Laboratory, Memorial Sloan-Kettering Cancer
2000-Present	Member, Bone Tumor Disease Committee, COG
2000-Present	Member, Biology and Translational Research Committee representing osteosarcoma, COG
2001-2011	Subcommittee Chair, Biology, Bone Tumor Disease Committee, COG
2004-Present	Director, Sarcoma Research Laboratory, Albert Einstein College of Medicine (AECOM)
2004-Present	Member, Albert Einstein Cancer Center, AECOM
2004-2010	Associate Professor of Molecular Pharmacology and Pediatrics, AECOM
2004-Present	Division Chief, Pediatric Hematology/Oncology, The Children's Hospital at Montefiore
2005-2011	Vice Chair, Bone Tumor Disease Committee, COG
2005-Present	Vice Chairman, Department of Pediatrics, The Children's Hospital at Montefiore
2006-Present	Chair, A COG Protocol for Collecting and Banking Osteosarcoma Specimens, AOST06B1
2006-2011	Member, SARC (Sarcoma Alliance for Research through Collaboration) Consortium Developmental Therapeutics Working Group
2009-2010	Member, Board of Trustees, The Connective Tissue Oncology Society
2010-Present	Professor of Pediatrics and Molecular Pharmacology, AECOM
2010-Present	Treasurer, The Connective Tissue Oncology Society
2011-Present	Member, SARC, Clinical Research Committee
2011-Present	Chair, Bone Tumor Disease Committee, COG

C. Selected peer-reviewed publications or manuscripts (170 published manuscripts)

1. Gorlick R, Goker E, Trippett T, et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335:1041-8 [review].



2. Gorlick R, Goker E, Trippett T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute leukemia and is associated with decreased reduced folate carrier expression. Blood 1997;89:1013-8.
3. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/ErbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-8.
4. García-Castellano JM, Villanueva A, Healey JH, …, Gorlick R. Methylthioadenosine phosphorylase (MTAP) gene deletions are observed frequently in osteosarcoma. Clin Cancer Res 2002;8:782-7.
5. Yang R, Mazza B, Sowers R, …, Gorlick R. Sequence alterations in the reduced folate carrier are observed frequently in osteosarcoma tumor samples. Clin Cancer Res 2003; 9:837-44.
6. Hoang BH, Kubo T, Healey JH, …, Gorlick R. Dickkopf 3 inhibits invasion and motility of SaOS-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004; 64:2734-9.
7. Laverdiere C, Hoang BH, Yang R, … Gorlick R. mRNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005; 11:2561-2567.
8. Yang R, Kolb EA, Qin J, … Gorlick R. The folate receptor alpha is frequently over-expressed in osteosarcoma samples and plays a role in the uptake of the physiological substrate, 5-methyl-tetrahydrofolate. Clin Cancer Res 2007;13:2557-2567.
9. Yang R, Piperdi S, Gorlick R. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res. 2008;14: 6396-6404.
10. Kubo T, Piperdi S, Rosenblum J, … Gorlick R. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008;112;2119-2129.
11. Levy AS, Meyers PA, Wexler LH, … Gorlick R. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer. 2009; 115:207-216. Epub Dec 2008.



12. Li N, Yang R, Zhang W, Dorfman H, Rao P, Gorlick R. Genetically transforming human mesenchymal stem cells to sarcomas: Changes in cellular phenotype and multilineage differentiation potential. Cancer, 2009; 115:4795-806. Epub Jul 2009.
13. Abdeen A, Chou AJ, Healey JH, … Gorlick R. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009;115:5243-50. Epub Aug 2009.
14. Meyers PA, Healey JH, Chou AJ, … Gorlick R. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer. 2011; 117:1736-1744. Epub Nov 2010.
15. Sowers R, Wenzel BD, Richardson C, … Gorlick R. Impairment of methotrexate transport is common in osteosarcoma tumor samples. Sarcoma. 2011; 2011:834170. Epub Dec 2010.

D. Research Support

Ongoing Research Support

COG Subcontract (CA98543-03) Adamson (PI) 12/01/98-11/30/13
NCI/Children's Oncology Group (COG)
"Bone Tumor Resource Laboratory and Bone Tumor Committee Chair"
The Bone Tumor Resource Laboratory is the resource laboratory for osteosarcoma fresh tissue for the Children's Oncology Group. This supports the procurement, processing and distribution of fresh tumor samples. It does not support the conduct of research studies.
Role: Subcontract PI

N01-CM-37027-01 Houghton (PI) 8/1/04-7/30/14
NCI



Pediatric Preclinical Testing Consortium
This contract supports testing of new chemotherapy agents in osteosarcoma xenografts.
Role: Subcontract PI

Swim Across America Gorlick (PI) 7/1/06-6/30/13
Developing Targeted Therapy for Osteosarcoma
This grant supports molecular analyses of signal transduction pathways in osteosarcoma cell lines and xenograft models to identify which may be relevant therapeutic targets.
Role: PI

New York Community Trust Gorlick (co-PI) 1/1/11-12/31/13
The Effect of Surgical Margins on Local Recurrence in Osteosarcoma
This grant supports preclinical studies to investigate the need for radical surgical margins with good chemotherapy responses
Role: co-PI

Program Director/Principal Investigator (Last, First, Middle):